Navipharm

Total Healthcare company who is responsible for human health from care to Cure.

2020

Launched ¡°Bicrome¡± for nose-care probiotics
of NVP-1703 in Korea
Signed a license-out agreement of NVP-1102 in Russia
Approved IND for clinical trial phase III of NVP-1805

2019

Approved IND for clinical trial phase III of NVP-1203
Launched NVP-1503 in Korea
Obtained individual recognition of functional ingredient
for NVP-1703 from MFDS
Initiated human study of functional probiotics
for NVP-1905

2018

Initiated human study of functional probiotics
for NVP-1704
Obtained Exclusive Marketing Approval
of NVP-1504 from MFDS

2017

Designated as ¡°Pharmaceutical Testing Laboratory¡±
by MFDS
Initiated human study of functional probiotics
for NVP-1702
Initiated human study of functional probiotics
for NVP-1703
line
line
line

2016

Relocated headquarters and Research Institute to
    new company building
Obtained a marketing approval of NVP-1205
     in Korea

2015

Signed a license-out agreement of NVP-0902
     in Mexico
Obtained a marketing approval of NVP-1102
     in Korea

2013

Signed a license-out agreement of NVP-0902
     with Roche
Obtained a marketing approval
     of NVP-0902 in Korea

2012

Signed a license-out agreement of NVP-1102

2011

Signed a license-out agreement of NVP-0902

2010

Signed an agreement with Thomson Reuters on providing and updating NCE & DMF Information in Korea
Registered as Venture Business Company and Company Affiliated Research Institute

2009

Moved into ¡°Gyeonggi Small and Medium Business Supporting Center¡± and established Research Institute

2008

Constructed and managed MFDS¡¯s Patent Informatics DB from August 2008 to December 2013
Founded Navipharm Co., Ltd.
line
line
tab

logo

EN KOR

Navipharm

Total Healthcare company who is responsible for human health from care to Cure.
hishishis